A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)
Motoki Yoshida(Osaka Medical and Pharmaceutical University), Akihito Tsuji(Kagawa University Hospital), Yasuhiro Miyake(High Energy Accelerator Research Organization), Koki Otsuka(Fujita Health University), Akinori Takagane(Iwate Medical University), Mutsumi Fukunaga(Sakai Municipal Hospital), Atsushi Satō(National Cancer Center Hospital East), Takao Takahashi(Keio University), Ken Shimada(Showa University Northern Yokohama Hospital), Naoki Nagata, Hidetomo Matsumoto(University of Miyazaki Hospital), Yutaka Ogata(Kurume University Medical Center), Tatsuo Kagimura(Foundation for Biomedical Research and Innovation)
Cited by 14
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
A new approach for measuring the muon anomalous magnetic moment and electric dipole moment
|Progress of Theoretical and Experimental Physics|2019|239